IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+13.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1B
AUM Growth
+$1B
(-1.4%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
99
New
22
Increased
29
Reduced
11
Closed
29
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29.8M |
| 2 |
Becton Dickinson
BDX
|
$17.5M |
| 3 |
Insmed
INSM
|
$16.8M |
| 4 |
Elevance Health
ELV
|
$16.3M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$14M |
Top Sells
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
$28.2M |
| 2 |
AbbVie
ABBV
|
$24.6M |
| 3 |
Intuitive Surgical
ISRG
|
$17.8M |
| 4 |
Charles River Laboratories
CRL
|
$17.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$16.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $104M | 9.87% | 1,550,000 +250,000 | +19% | +$16.8M |
|
2
Tenet Healthcare
THC
$16.3B
| $66.5M | 6.32% | 500,000 +75,000 | +18% | +$9.98M |
|
|
3
Cytokinetics
CYTK
$4.23B
| $54.2M | 5.15% | 1,000,000 +550,000 | +122% | +$29.8M |
|
4
Boston Scientific
BSX
$156B
| $50.1M | 4.76% | 650,000 +50,000 | +8% | +$3.85M |
|
|
5
Elevance Health
ELV
$71.8B
| $43.3M | 4.12% | 80,000 +30,000 | +60% | +$16.3M |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $36.6M | 3.48% | 340,000 +130,000 | +62% | +$14M |
|
7
Novartis
NVS
$245B
| $31.9M | 3.03% | 300,000 +75,000 | +33% | +$7.98M |
|
|
LBPH
8
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $29.7M | 2.82% | 1,100,000 +125,000 | +13% | +$3.38M |
|
9
Merck
MRK
$210B
| $29.1M | 2.76% | 235,000 | – | – |
|
10
Humana
HUM
$36.5B
| $28M | 2.66% | 75,000 +15,000 | +25% | +$5.6M |
|
11
Encompass Health
EHC
$12.3B
| $25.7M | 2.45% | 300,000 -50,000 | -14% | -$4.29M |
|
12
Universal Health Services
UHS
$11.6B
| $24M | 2.28% | 130,000 +5,000 | +4% | +$925K |
|
|
NARI
13
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $19.3M | 1.83% | 400,000 +200,000 | +100% | +$9.63M |
|
14
Vera Therapeutics
VERA
$1.38B
| $18.1M | 1.72% | 500,000 +140,000 | +39% | +$5.07M |
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $17.9M | 1.7% | 400,000 +75,000 | +23% | +$3.36M |
|
|
16
Becton Dickinson
BDX
$55.3B
| $17.5M | 1.67% | +75,000 | New | +$17.5M |
|
17
Cigna
CI
$80.3B
| $16.5M | 1.57% | 50,000 +10,000 | +25% | +$3.31M |
|
18
Tarsus Pharmaceuticals
TARS
$2.47B
| $16M | 1.52% | 590,000 | – | – |
|
19
Krystal Biotech
KRYS
$4.27B
| $15.6M | 1.48% | 85,000 +5,000 | +6% | +$918K |
|
20
Arcellx
ACLX
$3.85B
| $15.2M | 1.44% | 275,000 +20,000 | +8% | +$1.1M |
|
21
Icon
ICLR
$13.8B
| $14.1M | 1.34% | 45,000 | – | – |
|
22
Edwards Lifesciences
EW
$47.8B
| $13.9M | 1.32% | +150,000 | New | +$13.9M |
|
23
Thermo Fisher Scientific
TMO
$186B
| $13.8M | 1.31% | +25,000 | New | +$13.8M |
|
24
Quest Diagnostics
DGX
$20.3B
| $13.7M | 1.3% | +100,000 | New | +$13.7M |
|
25
Viking Therapeutics
VKTX
$3.04B
| $13.3M | 1.26% | 250,000 -200,000 | -44% | -$10.6M |
|